Financial Performance - Total revenues for Q3 2026 were $811.2 million, representing a 16% increase year over year from $699.2 million[3] - Subscription services revenues for Q3 2026 reached $682.5 million, up 17% year over year from $580.9 million[3] - Operating income for Q3 2026 was $240.9 million, a 33% increase from $181.4 million in the same quarter last year[3] - Non-GAAP operating income for Q3 2026 was $364.9 million, up 20% from $304.0 million year over year[3] - Net income for Q3 2026 was $236.2 million, reflecting a 27% increase from $185.8 million in Q3 2025[3] - Non-GAAP net income for Q3 2026 was $345.1 million, an increase of 20% from $288.3 million year over year[3] - Total revenues for the three months ended October 31, 2025, were $811,236,000, representing a 16% increase from $699,207,000 in the same period of 2024[17] - Subscription services revenue increased to $682,498,000 for the three months ended October 31, 2025, up 17.5% from $580,850,000 in 2024[17] - Net income for the nine months ended October 31, 2025, was $664,702,000, a 28.2% increase compared to $518,513,000 for the same period in 2024[20] - Operating income for the three months ended October 31, 2025, was $240,853,000, up 32.8% from $181,353,000 in 2024[17] - Diluted net income per share for the three months ended October 31, 2025, was $1.40, compared to $1.13 in 2024, representing a 23.9% increase[17] - Non-GAAP net income for the nine months ended October 31, 2025, was $1,006,343,000, up from $802,551,000 in 2024, reflecting a growth of 25.4%[29] Cash Flow and Expenses - Cash flows from operating activities for the nine months ended October 31, 2025, totaled $1,308,378,000, compared to $1,020,507,000 in 2024, reflecting a 28.2% increase[20] - Cash, cash equivalents, and restricted cash at the end of the period were $1,662,315,000, up from $1,046,689,000 in 2024[20] - Stock-based compensation expenses for the nine months ended October 31, 2025, amounted to $354,444,000, compared to $322,146,000 in 2024, reflecting a 10% increase[20] - Net cash provided by operating activities on a GAAP basis for the three months ended October 31, 2025, was $192,787,000, compared to $164,117,000 for the same period in 2024, representing a year-over-year increase of 17.4%[26] - Non-GAAP net cash provided by operating activities for the nine months ended October 31, 2025, was $1,285,076,000, up from $1,015,347,000 in 2024, reflecting a growth of 26.5%[26] Research and Development - Research and development expenses for the three months ended October 31, 2025, were $191,883,000, an increase of 11.3% from $172,411,000 in 2024[17] - Research and development expense on a GAAP basis for the three months ended October 31, 2025, was $191,883,000, compared to $172,411,000 in 2024, reflecting an increase of 11.4%[29] Guidance and Future Outlook - Guidance for Q4 2026 includes total revenues between $807 million and $810 million, with non-GAAP fully diluted net income per share expected to be approximately $1.92[8] - The company is on track to achieve a $6 billion revenue run-rate goal by 2030[3] Product Development - Veeva AI is set to release its first agents for CRM and commercial content in early December 2025, with additional agents planned for 2026[5] - Veeva Development Cloud applications were selected as the enterprise standard by three top 20 biopharmas in Q3 2026[5] Operating Expenses and Margins - Total operating expenses for the nine months ended October 31, 2025, were $1,120,325,000, compared to $1,004,076,000 in 2024, marking a 11.6% increase[17] - Operating margin on a non-GAAP basis for the three months ended October 31, 2025, was 45.0%, compared to 43.5% in 2024, indicating an improvement of 1.5 percentage points[29] - Sales and marketing expense on a GAAP basis for the three months ended October 31, 2025, was $110,552,000, an increase from $98,695,000 in 2024, representing a growth of 12.8%[29] - Gross margin on subscription services revenues on a non-GAAP basis increased to 87.0% for the nine months ended October 31, 2025, compared to 86.2% in 2024[26]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - Veeva Systems (VEEV) is expected to report quarterly earnings of $1.95 per share, an increase of 11.4% year-over-year, with revenues projected at $791.88 million, reflecting a 13.3% increase compared to the same period last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.1% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between these trends and short-term price performance [3]. Revenue Projections - Analysts project 'Revenues- Subscription services' to reach $671.02 million, indicating a year-over-year change of +15.5% [5]. - The consensus for 'Revenues- Professional services and other' is $120.86 million, reflecting a year-over-year change of +2.1% [5]. - 'Revenues- Professional services and other- Veeva R&D Solutions' is forecasted to be $74.66 million, showing a +3% change from the previous year [5]. - 'Revenues- Subscription services- Veeva R&D Solutions' is expected to reach $361.28 million, indicating a +19.4% change year-over-year [6]. - 'Revenues- Subscription services- Veeva Commercial Solutions' is projected at $309.72 million, reflecting an +11.3% change from the prior year [6]. - The estimate for 'Revenues- Professional services and other- Veeva Commercial Solutions' stands at $46.26 million, indicating a +0.9% change year-over-year [7]. Gross Margin Estimates - The estimated 'Non-GAAP Gross Margin- Professional Services and other' is projected at 31.8%, down from 33.5% reported in the same quarter last year [7]. - The collective assessment suggests a 'Non-GAAP Gross Margin- Subscription services' of 85.9%, slightly lower than the 86.2% reported in the same quarter last year [8]. Stock Performance - Veeva shares have shown a return of +3.4% over the past month, outperforming the Zacks S&P 500 composite's +1.5% change [8]. - With a Zacks Rank 2 (Buy), VEEV is expected to outperform the overall market in the near future [8].

Core Insights - Veeva Systems Inc. is recognized as a leading digital health stock, particularly in the life sciences sector [1] - The company announced that its Veeva Basics solution has been adopted by over 100 biotech firms, indicating strong market demand and scalability [2][5] - New capabilities include LIMS Basics for laboratory oversight and PromoMats Basics for content lifecycle management, enhancing operational efficiency for users [3][4] Company Overview - Veeva Systems Inc. operates as a cloud-software company focused on providing solutions for life sciences organizations, including clinical, regulatory, quality, and commercial platforms [6] - The Veeva Basics solution is built on the Vault Platform, allowing biotech firms to implement best practices quickly and transition smoothly to a full Vault solution [2][4] Market Position - The adoption of Veeva Basics by over 100 firms highlights Veeva's strategic growth within the emerging biotech segment, where regulatory compliance and cost efficiency are critical [5] - Testimonials from early adopters emphasize the benefits of pre-configured templates and rapid implementation, showcasing Veeva's value proposition in the market [4]

Company Performance - Veeva Systems (VEEV) closed at $291.70, down 1.77% from the previous trading session, underperforming compared to the S&P 500's loss of 1.66% [1] - The stock has increased by 3.33% over the past month, which is lower than the Medical sector's gain of 6.4% and the S&P 500's gain of 4.64% [1] Upcoming Earnings - Veeva Systems is set to release its earnings report on November 20, 2025, with projected earnings of $1.95 per share, reflecting a year-over-year growth of 11.43% [2] - The consensus estimate for quarterly revenue is $791.88 million, indicating a 13.25% increase from the same period last year [2] Full Year Estimates - For the full year, earnings are projected at $7.78 per share and revenue at $3.14 billion, showing increases of 17.88% and 14.26% respectively from the previous year [3] Analyst Estimates and Stock Performance - Changes in analyst estimates for Veeva Systems are closely monitored, as positive revisions indicate optimism about the business outlook [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Veeva Systems at 2 (Buy) [5] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 38.18, which is higher than the industry average of 34.81 [5] - The company has a PEG ratio of 1.63, compared to the Medical Info Systems industry's average PEG ratio of 3.09 [6] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 72, placing it in the top 30% of over 250 industries [6][7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Group 1 - The stock of Veeva Systems Inc. (VEEV) is experiencing significant attention due to high implied volatility in the options market, particularly for the Jan 16, 2026 $330.00 Put option [1] - Implied volatility indicates the market's expectation of future movement, suggesting that investors anticipate a significant price change or an upcoming event that could lead to a major rally or sell-off [2] - Veeva Systems holds a Zacks Rank 2 (Buy) in the Medical Info Systems Industry, which is in the top 26% of the Zacks Industry Rank, indicating a positive outlook [3] Group 2 - Over the past 60 days, one analyst has raised the earnings estimate for Veeva Systems for the current quarter, resulting in a consensus estimate increase from $1.94 to $1.95 per share [3] - The high implied volatility may indicate a developing trading opportunity, as options traders often seek to sell premium on options with high implied volatility to capture decay [4]

Core Insights - Veeva Systems has announced that over 100 biotech companies have adopted Veeva Basics to enhance their operations in clinical, regulatory, and quality areas [1][11] - The introduction of new applications, Veeva LIMS Basics and PromoMats Basics, is aimed at addressing critical quality control and commercial needs, with availability expected in early 2026 [4][10] Group 1: Veeva Basics Overview - Veeva Basics offers pre-configured and pre-validated applications for rapid deployment, built on the Vault Platform, allowing seamless transition to a full Vault solution without migration [2] - The solution is designed to support efficient processes across key business areas, providing technology and support for both current and future needs [2] Group 2: Industry Adoption and Feedback - At the Veeva R&D and Quality Summit in Boston, over 100 biotech leaders from 60 companies gathered to discuss the impact of Veeva Basics on emerging biotechs [3] - Feedback from industry leaders highlights the value of Veeva Basics in standardizing processes and providing agile solutions that can scale with company growth [5][6][7] Group 3: New Applications - Veeva LIMS Basics will enable oversight for virtual companies, including batch release and certificate of analysis capabilities, with stability functionality planned for 2026 [10] - PromoMats Basics will facilitate full content lifecycle management, covering approval, storage, and distribution of promotional content [10] Group 4: Company Background - Veeva Systems serves over 1,500 customers, including large biopharmaceutical companies and emerging biotechs, focusing on innovation, product excellence, and customer success [8]

Core Points - Veeva Systems will announce its financial results for the third quarter ending October 31, 2025, after market close on November 20, 2025 [1] - A conference call and webcast will be held on the same day at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results [1][3] - Prepared remarks will be posted on Veeva's investor relations website at approximately 1:05 p.m. PT (4:05 p.m. ET) [2] Company Overview - Veeva Systems provides industry cloud solutions for life sciences, including software, data, and business consulting [3] - The company serves over 1,500 customers, ranging from large pharmaceutical companies to emerging biotechs [3] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves [3]

Company Overview - Veeva Systems (NYSE: VEEV) is recognized for its excellent financial performance and high growth rates, with the added advantage of having no debt [1] Financial Performance - The company demonstrates strong financial metrics, which are appealing to conservative investors [1] Investment Perspective - The business model of Veeva Systems is viewed positively, indicating potential for continued growth and stability in the market [1]

Core Insights - The stock market is showing signs of complacency regarding a potential weakening macroeconomy and an intensifying trade war as 2025 approaches [1] Group 1: Market Conditions - Investors need to be cautious in deploying smart strategies amid the backdrop of a potentially weakening macroeconomy and trade tensions [1] Group 2: Analyst Background - Gary Alexander has extensive experience covering technology companies on Wall Street and working in Silicon Valley, contributing to insights on industry themes [1] - He has been a contributor on Seeking Alpha since 2017 and has been quoted in various web publications, with his articles syndicated to popular trading apps like Robinhood [1]